BFFLD - LITHIUM HYDROXIDE

  • MSDS: BFFLD
  • Manufacturer: POLY RESEARCH CORP
  • Product Name: LITHIUM HYDROXIDE
  • National Stock Number: 6810-00-559-3261
Product Identification

Product ID:LITHIUM HYDROXIDE
MSDS Date:10/06/1998
FSC:6810
NIIN:00-559-3261
MSDS Number: BFFLD

Responsible Party
POLY RESEARCH CORPORATION
125 CORPORATE DRIVE
HOLTSVILLE, NY 11742
US

Emergency Phone: 516-758-0460

Info Phone: 516-758-0460

Cage: 64713

Contractor
TANGRAM COMPANY LLC
HOLTSVILLE, NY 11742 US

Telephone: 631-758-0460

Cage: 1H2F5

Ingredients

LITHIUM HYDROXIDE

CAS: 1310-65-2

RTECS: OJ6307070

Hazards

LD50 LC50 Mixture:NO DATA PROVIDED BY MANUFACTURER
Routes of Entry: Inhalation:YES Skin:NO Ingestion:YES
Reports of Carcinogenicity:NTP:NO IARC:NO OSHA:NO
Health Hazards Acute and Chronic:ACUTE- THIS MATERIAL IS CORROSIVE TO
SKIN, EYES (MAY CAUSE BLINDNESS), NOSE, THROAT, RESPIRATORY &
GASTROINTESTINAL TRACTS. THE USE OF THIS PRODUCT IN INDUSTRIAL &
COMMERCIAL APPLICATIONS PRESENTS NO SIGNIFICANT TOXICITY HAZARD.
CHRONIC- UNKNOWN. TARGET ORGANS: N/P.
Explanation of Carcinogenicity:PRODUCT IS NOT INDICATED TO BE
CARCINOGENIC.
Effects of Overexposure:LITHIUM CARBONATE IS USED THERAPEUTICALLY AT
500-2000 MG/DAY ORAL DOSES FOR SPECIFIC METAL DISORDERS.
THERAPEUTIC EFFECTS OCCUR AAT BLOOD LEVELS OF 2.8-8.3 MG LITHIUM
PER LITER. MINIMAL SIGNS OF TOXIC ITY MAY ALSO OCCUR AT THESE
THERAPEUTIC LEVELS AND INVOLVE PRIMARILY GASTROINTESTINAL UPSET.
INCREASED DOSAGES CAN PRODUCE TREMORS, DROWSINESS AND INSTEADY
GAIT. SIGNS OF TOXICITY RESOLVE RAPIDLY ON C ESSATION OF TREATMENT.
PROLONGED TREATMENT AT TOXIC LEVELS RESULT IN DEHYDRATION, KIDNEY
DAMAGE, WEIGHT LOW AND THYROID DISTURBANCES.
Medical Cond Aggravated by Exposure:NO APPLICABLE DATA WAS FOUND.

First Aid

First Aid:EYES: IMMEDIATELY FLUSH WITH WATER FOR 15 MINUTES, LIFIING
UPPER AND LOWER LIDS OCCASIONALLY. IMMEDIATELY SEE A PHYSICIAN.
SKIN: IMMEDIATELY FLUSH WITH PLENTY OF WATER. IF IRRITATION
PERSISTS SEEK MED ICAL ATTENTION. INHALATION: REMOVE TO FRESH AIR.
SUPPORT RESPIRATION IF NECESSARY. IF BREATHING DISCOMFORT OCCURS
AND PERSISTS, SEE A PHYSICIAN. INGESTION: DRINK TWO GLASSES OF
WATER. DO NOT INDUCE VO MITING! DO NOT GIVE ANYTHING BY MOUTH TO AN
UNCONSCIOUS PERSON. SEE A PHYSICIAN IMMEDIATELY.

Fire Fighting

Extinguishing Media:ANY SUITABLE FOR SURROUNDING FIRE.
Fire Fighting Procedures:NONE.
Unusual Fire/Explosion Hazard:NONE, THIS PRODUCT IS NOT AN EXPLOSIVE.

Accidental Release

Spill Release Procedures:SWEEP UP AND PLACE IN SUITABLE CONTAINER.
Neutralizing Agent:DLA-HMIS: WEAK ACID.

Handling

Handling and Storage Precautions:DO NOT GET IN EYES, ON SKIN OR
CLOTHING. AVOID BREATHING THE DUST. KEEP CONTAINER CLOSED. STORE
AWAY FROM ACIDS AND WATER. WASH THOROUGHLY AFTER HANDLING.
Other Precautions:NO DATA PROVIDED BY MANUFACTURER

Exposure Controls

Respiratory Protection:WEAR NIOSH/MSHA APPROVED RESPIRATOR WHEN
ADEQUATE VENTILATION IS NOT AVAILABLE.
Ventilation:USE WITH ADEQUATE VENTILATION.
Protective Gloves:RUBBER
Eye Protection:SAFETY GLASSES WITH SIDE SHIELDS, CHEMICAL WORKERS
DUST-PROOF GOGGLES
Other Protective Equipment:QUICK DRENCH EYE WASH & SAFETY SHOWER.
Work Hygienic Practices:WASH THOROUGHLY AFTER HANDLING.
Supplemental Safety and Health
NOTE TO PHYSICIAN: LITHIUM HYDROXIDE HAS HIGH INHALATION CORROSIVITY
AND IS CORROSIVE BY INGESTION. REMOVAL OF EXPOSURE SHOULD BE
IMMEDIATE, USING LARGE AMOUNTS OF WATER & GASTRIC GAVAGE IF
NECESSARY. TREATMENT IS OTHERWISE SYMPTOMATIC AND SUPPORTIVE.

Chemical Properties

HCC:B1
Melt/Freeze Pt:=470.C, 878.F
Decomp Temp:=924.C, 1695.2F
Spec Gravity:1.5
Evaporation Rate & Reference:N/A (BUTYL ACETATE=1)
Solubility in Water:10% @25C
Appearance and Odor:WHITE CRYSTALS - ODORLESS

Stability

Stability Indicator/Materials to Avoid:YES
STRONG ACIDS, ALUMINUM, ZINC
Stability Condition to Avoid:REACTS WITH ACIDS.
Hazardous Decomposition Products:NONE.

Disposal

Waste Disposal Methods:DISPOSE OF WASTE ACCORDING TO FEDERAL EPA, STATE
AND LOCAL REGULATIONS.

Toxicology

Toxicological Information:SOME STUDIES OF PREGNANT MICE AND RATS WERE
ASSOCIATED WITH BIRTH DEFECTS BUT ONLY AT DOSE LEVELS LARGE ENOUGH
TO PRODUCE SIGNS OF SEVERE MATERNAL TOXICITY. ALTHOUGH DATA FROM
THE 1970'S AND EARLY 198 0'S SUGGESTED AN INCREASE IN CARDIOVASCULR
DEFECTS IN BABIES BORN TO WOMEN ON LITHIUM CARBONATE THERAPY, MORE
RECENT STUDIES HAVE FOUND NO ASSOCIATION BETWEEN LITHIUM EXPOSURE
AND BIRTH DEFECTS. WOMEN RECEIVING THERAPEUTIC LITHIUM CARBONATE
TREATMENT AT THE TIME OF CONFINEMENT HAVE THE POTENTIAL FOR
DELIVERY OF A FETUS WITH POOR MUSCLE TONE, SLOW HEART RATE AND
CYANOSIS. FULL RECOVERY USUALLY OCCU RS WITHIN 2-10 DAYS POST
PARTUM.

Other Information

Disclaimer (provided with this information by the compiling agencies):
This information is formulated for use by elements of the Department
of Defense. The United States of America in no manner whatsoever,
expressly or implied, warrants this information to be accurate and
disclaims all liability for its use. Any person utilizing this
document should seek competent professional advice to verify and
assume responsibility for the suitability of this information to their
particular situation.

Ecology

Ecological:NO DATA PROVIDED BY MANUFACTURER.

Transport

Transport Information:CORROSIVE SOLID, N.O.S., 8, UN1759, PG II.
FOREIGN: LITHIUM HYDROXIDE, MONOHYDRTAE, CORROSIVE MATERIAL UN2680.

Regulatory

SARA Title III Information:NOT LISTED IN SARA TITLE III.
Federal Regulatory Information:TSCA INVENTORY STATUS: LISTED.
REPORTABLE QUANTITY (RQ) UN US EPA CERCLA: NO DATA PROVIDED BY
MANUFACTURER.
State Regulatory Information:RIGHT-TO-KNOW:CALIFORNIA:LISTED AS A
REPRODUCTIVE TOXIN.